Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer

Table S1 Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching Table S2 Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching Table S3 Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49%